Voobon Ventures May Fund The Breakthrough for Cancer Treatment

May 20, 2009 - PRLog -- Voobon Ventures has expressed a great interest in partnering with Kalos Therapeutics, founder of the patented cancer treatment, KT-220 ANP.

Kalos Therapeutics is a new drug development company with a unique opportunity to treat cancer by utilizing an endogenous family of peptides in-licensed from the University of South Florida.  Since December 2005, as a fully fledged research and development organization, Kalos Therapeutics, has emerged with the exclusive patent to develop the KT-220 ANP (atrial natriuretic peptide) family of peptides as a new therapeutic for the treatment of cancer. ANPs, were discovered in 1987, but their activity in oncology was only recently discovered in 2004 by Dr. Vesely.  Kalos has assembled a team of executives from industry-leading biotech and pharmacy companies, such as Pfizer, Upjohn, Biogen-Idec and Roche/Chugai.

KT-220 ANP, which is derived from the heart, was discovered in 2004 in the laboratory of Dr. David Vesely, Chief of Endocrinology at the James Haley Veterans Medical Center in Tampa and a Professor of Medicine at the University of South Florida.  KT-220 has been shown to be anti-proliferative against over twelve cancer cell lines at micromolar concentrations in both normal MAPK & constitutively activated MAPK cells lines. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, and colon cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer. KT-220 has been used in a previous trial for acute heart failure in 88 human subjects where no relevant adverse effects were reported. Its effect on cancer are patented and exclusively licensed to Kalos.

"Cancer is still among the top killers in our society today,” said Mark Shariar, President and Managing Director of Voobon Ventures. “If there was ever a way for Voobon Ventures to be involved in saving human lives, this is it. We are very excited to be in negotiations for a partnership with Kalos Therapeutics, who has discovered an evolutionary breakthrough in cancer treatment.”

About Voobon Ventures, Inc.

Voobon Ventures, Inc. headquartered in Atlanta, Georgia with offices in New York City, Chicago, Las Vegas, Las Angeles and London is a closely held venture capital firm, with managed funds under $5 billion. Under the direction of its President and Managing Director, Mark Shariar, its investment clients have selected Voobon Ventures based upon consistent sound returns in a tough economy and the privacy offered through the fund. Voobon is actively engaged in both short and long term investments with its long term primarily focused on leading edge companies in the communications, entertainment, technology, medical technology, real estate, manufacturing, mining and energy industries. Additional information is available at www.voobonventures.com.

# # #

Unique-integrated Venture Capital Management, Private Equity Investments, and Business Development Firm